The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Nuclear EGFR contributes to acquired resistance to cetuximab
Open accessAbstract
Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma and metastatic colorectal cancer. Previous reports have shown that EGFR translocation to the nucleus is associated with cell proliferation. Here we investigated mechanisms of acquired resistance to cetuximab using a model derived from the non-small cell lung cancer line H226. We demonstrated that cetuximab-resistant cells overexpress HER family ligands including epidermal growth factor (EGF), amphiregulin, heparin-binding EGF and β-cellulin. Overexpression of these ligands is associated with the nuclear translocation of the EGFR and this process was mediated by the Src family kinases (SFK). Treatment of cetuximab-resistant cells with the SFK inhibitor, dasatinib, resulted in loss of nuclear EGFR, increased membrane expression of the EGFR and resensitization to cetuximab. In addition, expression of a nuclear localization sequence-tagged EGFR in cetuximab-sensitive cells increased resistance to cetuximab both in vitro and in mouse xenografts. Collectively, these data suggest that nuclear expression of EGFR may be an important molecular determinant of resistance to cetuximab therapy and provides a rationale for investigating nuclear EGFR as a biomarker for cetuximab response. Further, these data suggest a rationale for the design of clinical trials that examine the value of treating patients with cetuximab-resistant tumors with inhibitors of SFKs in combination with cetuximab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Response to these agents appears to be limited by intrinsic as well as acquired resistance (Gupta et al., 2002; Arteaga, 2003; Viloria-Petit and Kerbel, 2004; Bianco et al., 2005; Camp et al., 2005; Kobayashi et al., 2005; Pao et al., 2005).”
BackgroundNuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase
Ni, C.-Y., Murphy, M. P., Golde, T. E., & Carpenter, G. (2001) · Science · doi:10.1126/science.1065412 · Cited by 856
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550
Self-citationNuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Lo, H.-W., Hsu, S.-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y., & Hung, M.-C. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 544
Dittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., Chen, D. J., Kehlbach, R., & Rodemann, H. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506591200 · Cited by 529
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497
Sunnarborg, S. W., Hinkle, C. L., Stevenson, M., Russell, W. E., Raska, C. S., Peschon, J. J., Castner, B. J., Gerhart, M. J., Paxton, R. J., Black, R. A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112050200 · Cited by 413
Gupta, A., McKenna, W. G., Weber, C. N., Feldman, M. D., Goldsmith, J. D., Mick, R., Machtay, M. X., Rosenthal, D. I., Bakanauskas, V. J., Cerniglia, G. J., et al. (2002) · PubMed · Cited by 343
Lo, H.-W., & Hung, M.-C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602941 · Cited by 323
Tyrosine phosphorylation controls PCNA function through protein stability
Wang, S.-C., Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Yang, C.-C., McIntush, E. W., Li, L.-Y., Hawke, D. H., Kobayashi, R., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1501 · Cited by 322
Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S., Lindeman, N., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 318
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
Wang, S.-C., Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Lee, D.-F., Bartholomeusz, G., Ou-Yang, F., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.012 · Cited by 305
Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
Lo, H.-W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.-F., & Hung, M.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.338.65.1 · Cited by 290
TACE is required for the activation of the EGFR by TGF-α in tumors
Borrell-Pagès, M., Rojo, F., Albanell, J., Baselga, J., & Arribas, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg111 · Cited by 274
Psyrri, A., Yu, Z., Weinberger, P. M., Sasaki, C., Haffty, B., Camp, R., Rimm, D., & Burtness, B. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0420 · Cited by 269
Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family
Hsu, S.-C., & Hung, M.-C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610014200 · Cited by 260
Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor
Giri, D. K., Ali-Seyed, M., Li, L.-Y., Lee, D.-F., Ling, P., Bartholomeusz, G., Wang, S.-C., & Hung, M.-C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11005-11018.2005 · Cited by 244
Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1
Lo, H., Ali‐Seyed, M., Wu, Y., Bartholomeusz, G., Hsu, S., & Hung, M. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20876 · Cited by 240
Lo, H.-W., Hsu, S.-C., & Hung, M.-C. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9011-0 · Cited by 237
Dissection of the Inflammatory Bowel Disease Transcriptome Using Genome-Wide cDNA Microarrays
Costello, C. M., Mah, N., Häsler, R., Rosenstiel, P., Waetzig, G. H., Hahn, A., Lu, T., Gurbuz, Y., Nikolaus, S., Albrecht, M., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020199 · Cited by 231
Bandyopadhyay, D., Mandal, M., Adam, L., Mendelsohn, J., & Kumar, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1568 · Cited by 229
Micronutrient Sprinkles to Control Childhood Anaemia
Zlotkin, S. H., Schauer, C., Christofides, A., Sharieff, W., Tondeur, M. C., & Hyder, S. M. Z. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020001 · Cited by 224
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
Camp, E. R., Summy, J., Bauer, T. W., Liu, W., Gallick, G. E., & Ellis, L. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.397.11.1 · Cited by 210
Offterdinger, M., Schöfer, C., Weipoltshammer, K., & Grunt, T. W. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200109033 · Cited by 208
Hung, L.-Y., Tseng, J. T., Lee, Y.-C., Xia, W., Wang, Y.-N., Wu, M.-L., Chuang, Y.-H., Lai, C.-H., & Chang, W.-C. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn417 · Cited by 196
Co‐regulation of B‐Myb expression by E2F1 and EGF receptor
Hanada, N., Lo, H., Day, C., Pan, Y., Nakajima, Y., & Hung, M. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20147 · Cited by 188
Role of the Sec61 Translocon in EGF Receptor Trafficking to the Nucleus and Gene Expression
Liao, H.-J., & Carpenter, G. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-09-0802 · Cited by 187
Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0589 · Cited by 170
Wheeler, D. L., Iida, M., Kruser, T. J., Nechrebecki, M. M., Dunn, E. F., Armstrong, E. A., Huang, S., & Harari, P. M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7903 · Cited by 157
Self-citationXia, W., Wei, Y., Du, Y., Liu, J., Chang, B., Yu, Y., Huo, L., Miller, S. A., & Hung, M. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20504 · Cited by 151
Xie, Y., & Hung, M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2368 · Cited by 134
Localization of epidermal growth factor receptor in hepatocyte nuclei
Marti, U., Burwen, S. J., Wells, A. H., Barker, M. E., Huling, S. L., Feren, A. M., & Jones, A. L. (1991) · Hepatology · doi:10.1002/hep.1840130104 · Cited by 129
Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies
Viloria‐Petit, A., & Kerbel, R. S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.091 · Cited by 104
Friedmann, B. J., Caplin, M. E., Savic, B., Shah, T., Lord, C. J., Ashworth, A., Hartley, J. A., & Hochhauser, D. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0239 · Cited by 103
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
Bianco, R., Troiani, T., Tortora, G., & Ciardiello, F. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00999 · Cited by 98
The developing role of receptors and adaptors
Massie, C. E., & Mills, I. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1882 · Cited by 74
Cao, H., Lei, Z. M., Bian, L., & Rao, C. V. (1995) · Endocrinology · doi:10.1210/endo.136.7.7540549 · Cited by 69
A Novel Mechanism of Resistance to Epidermal Growth Factor Receptor Antagonism In vivo
Rajput, A., Koterba, A. P., Kreisberg, J. I., Foster, J. M., Willson, J. K. V., & Brattain, M. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2773 · Cited by 52
The Role of Surgery in N2 Non–Small Cell Lung Cancer
DeCamp, M. M., Ashiku, S. K., & Thurer, R. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-9013 · Cited by 42
Psyrri, A. K., Egleston, B. L., Pectasides, E., Weinberger, P., Yu, Z., Kowalski, D. P., Sasaki, C. T., Haffty, B. G., Rimm, D. L., & Burtness, B. A. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2684 · Cited by 40
(2001) · PubMed
Research works printed but not linked: 1
- Arteaga CL . (2003). EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 21: 289s–2291s. · doi:10.1200/jco.2003.10.523
Cited by
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Self-citationAmplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Roock, W. D., Vriendt, V. D., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 603
Metadata
- Authors
- Li, C., Iida, M., Dunn, E. F., Ghia, A. J., & Wheeler, D. L.
- Venue
- Oncogene
- Published
- 2009-08-17
- Volume
- 28
- Issue
- 43
- Pages
- 3801-3813
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1996275566
- Cited by
- 313
- References
- 44
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.